By: P. Dirix MD, PhD, P. Westerlinck MD, G. Buelens MD, P. Huget MD, P. Meijnders MD, PhD
Skeletal involvement is very common in metastatic prostate cancer and is associated with (symptomatic) skeletal-related events. This article examines the clinical trial data that support the use of available bone-targeted therapies in prostate cancer.
(BELG J MED ONCOL 2016;10(3):97–100)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
